Published in Antimicrob Agents Chemother on May 26, 2009
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. Antimicrob Agents Chemother (2009) 0.80
From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-Festinavir. Curr Pharm Des (2013) 0.77
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther (2000) 3.52
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem (2001) 2.31
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med (1999) 2.07
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS (2004) 1.67
Twenty years of therapy for HIV-1 infection. Nat Med (2003) 1.62
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2007) 1.43
Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res (2002) 1.26
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr (2005) 1.10
Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol (2005) 1.06
Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res (2007) 1.03
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol (2003) 1.03
Cell entry and export of nucleoside analogues. Virus Res (2005) 1.03
Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res (2006) 1.01
Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother (2004) 0.98
Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. Bioorg Med Chem Lett (2003) 0.98
Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother (1998) 0.97
Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro. Antimicrob Agents Chemother (2005) 0.97
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob Agents Chemother (2007) 0.93
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother (2007) 0.91
Binding of nitrobenzylthioinosine to high-affinity sites on the nucleoside-transport mechanism of HeLa cells. Biochem J (1981) 0.90
Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol (2004) 0.89
A new rapid assay for measuring deoxycytidylate- and deoxythymidylate-kinase activities. Anal Biochem (1974) 0.86
Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity (2003) 1.97
Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol (2007) 1.45
Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood (2003) 1.41
The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J Neurosci (2006) 1.28
Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials (2007) 1.15
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol (2003) 1.03
Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res (2006) 1.01
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother (2005) 1.00
Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother (2004) 0.98
Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. Bioorg Med Chem Lett (2003) 0.98
Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro. Antimicrob Agents Chemother (2005) 0.97
X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res (2002) 0.97
Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun (2005) 0.96
The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials (2011) 0.96
Rationale of 5-(125)I-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med (2002) 0.95
Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis (2006) 0.94
Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob Agents Chemother (2007) 0.93
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. J Med Chem (2006) 0.91
Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol (2004) 0.91
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother (2007) 0.91
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem (2006) 0.90
Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunol Lett (2009) 0.90
Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol (2004) 0.89
Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology (2005) 0.89
Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice. Immunol Lett (2011) 0.89
Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate. Antimicrob Agents Chemother (2008) 0.88
Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase. Mol Pharmacol (2012) 0.88
Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol (2007) 0.88
Stereoselective synthesis of 1'-C-branched arabinofuranosyl nucleosides via anomeric radicals generated by 1,2-acyloxy migration. J Org Chem (2003) 0.87
Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring. J Med Chem (2004) 0.87
Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J Med Virol (2008) 0.86
Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. Nucl Med Biol (2003) 0.86
4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants. Antivir Chem Chemother (2005) 0.86
Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha. Antiviral Res (2004) 0.85
Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles. Biochem Biophys Res Commun (2009) 0.85
CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives. Chem Pharm Bull (Tokyo) (2004) 0.85
Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol (2003) 0.85
Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction. Antimicrob Agents Chemother (2012) 0.84
Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1. Retrovirology (2013) 0.84
TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol (2005) 0.83
The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother (2005) 0.83
Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety. Bioorg Med Chem (2005) 0.83
Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives. Biochem Biophys Res Commun (2011) 0.83
AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres. J Control Release (2005) 0.82
Sulfur extrusion with tin radical: synthesis of 4',5'-didehydro-5'-deoxy-5'-(tributylstannyl)adenosine, an intermediate for potential inhibitors against S-adenosyl homocysteine hydrolase. J Org Chem (2004) 0.82
HIV-1-infected macrophages induce astrogliosis by SDF-1alpha and matrix metalloproteinases. Biochem Biophys Res Commun (2005) 0.82
Stereoselective synthesis of the beta-anomer of 4'-thionucleosides based on electrophilic glycosidation to 4-thiofuranoid glycals. J Org Chem (2002) 0.81
Inhibitory effect of cepharanthine on dendritic cell activation and function. Int Immunopharmacol (2011) 0.81
Synthesis and anti-HIV activity of 4'-substituted 4'-thiothymidines: a new entry based on nucleophilic substitution of the 4'-acetoxy group. J Med Chem (2008) 0.81
Induction of thymidine phosphorylase expression by AZT contributes to enhancement of 5'-DFUR cytotoxicity. Cancer Lett (2006) 0.80
Sustained inhibition of HIV-1 replication by conditional expression of the E. coli-derived endoribonuclease MazF in CD4+ T cells. Hum Gene Ther Methods (2013) 0.80
Synthesis and anti-HIV activity of 4'-cyano-2',3'-didehydro-3'-deoxythymidine. Nucleosides Nucleotides Nucleic Acids (2004) 0.80
Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice. J Med Virol (2002) 0.80
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. Antimicrob Agents Chemother (2009) 0.80
Size effect of amphiphilic poly(γ-glutamic acid) nanoparticles on cellular uptake and maturation of dendritic cells in vivo. Acta Biomater (2013) 0.79
Ring opening of nucleoside 1',2'-epoxides with organoaluminum reagents: stereoselective entry to ribonucleosides branched at the anomeric position. J Org Chem (2004) 0.79
Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates. Mol Pharmacol (2004) 0.79
Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus. Vaccine (2010) 0.79
Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives. Antimicrob Agents Chemother (2012) 0.79
Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(gamma-glutamic acid) nanoparticles. Clin Vaccine Immunol (2010) 0.79
Short communication: a single step assay for rapid evaluation of inhibitors targeting HIV type 1 Tat-mediated long terminal repeat transactivation. AIDS Res Hum Retroviruses (2011) 0.79
An access to the β-anomer of 4'-thio-C-ribonucleosides: hydroboration of 1-C-aryl- or 1-C-heteroaryl-4-thiofuranoid glycals and its regiochemical outcome. J Org Chem (2011) 0.78
Synthesis and antiviral activities of 1'-carbon-substituted 4'-thiothymidines. Bioorg Med Chem (2004) 0.78
Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. J Med Virol (2005) 0.78
Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. Bioorg Med Chem (2005) 0.78
Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests. J Clin Microbiol (2003) 0.78
Ring opening of 4',5'-epoxynucleosides: a novel stereoselective entry to 4'-C-branched nucleosides. Org Lett (2003) 0.78
Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101. Antivir Chem Chemother (2007) 0.78
Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. Bioorg Med Chem (2004) 0.78
Nucleophilic substitution at the 4'-position of nucleosides: new access to a promising anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. J Org Chem (2006) 0.77
Effective induction of cell death on adult T-cell leukaemia cells by HLA-DRbeta-specific small antibody fragment isolated from human antibody phage library. J Biochem (2009) 0.77
Nucleophilic addition of benzenethiol to 1',2'-unsaturated nucleosides: 1'-C-phenylthio-2'-deoxynucleosides as anomeric radical precursors. J Org Chem (2002) 0.77
Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. Antivir Chem Chemother (2009) 0.77
Synthesis of 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives with potential anti-HIV activity. Antivir Chem Chemother (2011) 0.77
[Development of vaccine adjuvants using polymeric nanoparticles and their potential applications for anti-HIV vaccine]. Yakugaku Zasshi (2007) 0.77
5-Exo versus 6-endo cyclization of nucleoside 2-sila-5-hexenyl radicals: reaction of 6-(bromomethyl)dimethylsilyl 1',2'-unsaturated uridines. J Org Chem (2005) 0.77
Anti versus syn opening of epoxides derived from 9-(3-deoxy-beta-D-glycero-pent-3-enofuranosyl)adenine with Me3Al: factors controlling the stereoselectivity. J Org Chem (2006) 0.77
Gamma-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity. Bioorg Med Chem (2008) 0.77
From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-Festinavir. Curr Pharm Des (2013) 0.77
Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton. Bioorg Med Chem (2010) 0.77
A conformational mimetic approach for the synthesis of carbocyclic nucleosides as anti-HCV leads. ChemMedChem (2013) 0.77
High-sensitivity analysis of naturally occurring sugar chains, using a novel fluorescent linker molecule. J Biochem (2009) 0.77
Establishment of an in vitro assay system mimicking human immunodeficiency virus type 1-induced neural cell death and evaluation of inhibitors thereof. J Virol Methods (2003) 0.77
Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative k-37. Mol Pharmacol (2002) 0.76
Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines. J Med Chem (2006) 0.76
Synthesis of (+/-)-4'-ethynyl and 4'-cyano carbocyclic analogues of stavudine (d4T). Nucleosides Nucleotides Nucleic Acids (2005) 0.76
Synthesis of novel 4'-modified neplanocin A analogues and their inhibitory activity against S-adenosyl-L-l-homocysteine hydrolase. Nucleosides Nucleotides Nucleic Acids (2007) 0.76
Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Mol Pharm (2012) 0.76